Key points are not available for this paper at this time.
Low ALC at the time of CMV treatment completion was a strong independent predictor for recurrent CMV disease. This finding is biologically plausible given the known importance of T-cell immunity in maintaining CMV latency. Future studies should consider this inexpensive, readily available marker of host immunity.
Gardiner et al. (Sat,) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: